Skip to main content
SpringerLink
Log in

Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

We studied cellular proliferation by measuring the tritiated thymidine labeling index (TLI) in slices of primary invasive breast carcinomas. Estrogen receptor (ER) and progesterone receptor (PgR) were measured by ligand-binding assay.

The TLI was a strong independent predictor of survival and relapse-free survival in women with or without axillary lymph nodal metastases and in American Joint Committee stage I. In operable node-negative women treated surgically, predicted survival at 5 years was 89 ± 4% (probability±standard error) for 81 patients with low TLI (⩽3%), 64 ± 7% for 101 with mid TLI (3.1 – 8%), and 66 ± 6% for 86 with high TLI (>8%) (P = 0.001). Probabilities of survival for patients with positive axillary nodes were 79 ± 6% for 86 with low, 71 ± 7% for 71 with mid, and 52 ± 6% for 89 with high TLI (P = 0.0002). In stage I patients (tumor diameter not exceeding 2 cm), 5-year survival probabilities were 93 ± 4% in 70 with low, 72 ± 8% in 43 with mid, and 58 ± 10% in 35 with high TLI, (P = 0.0005). The TLI was predictive for survival and relapse-free survival within subgroups positive and negative for ER and positive for PgR (P<0.05) in stage I patients, and a predictive trend was observed in the PgR-negative subgroup (P = 0.16). TLI also predicted within different categories of vascular invasion and nuclear grade.

A stepwise Cox proportional hazards model selected TLI, number of positive axillary lymph nodes, and maximum diameter of the breast carcinoma as independent variables predictive of relapse, and added ER as a fourth variable for prediction of survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669–4671, 1977

    PubMed  Google Scholar 

  2. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 309: 1343–1347, 1983

    PubMed  Google Scholar 

  3. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP: The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 33: 441–445, 1984

    PubMed  Google Scholar 

  4. Meyer JS, Friedman E, McCrate MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983

    PubMed  Google Scholar 

  5. Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985

    PubMed  Google Scholar 

  6. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986

    PubMed  Google Scholar 

  7. American Joint Committee for Cancer Staging and End-Results Reporting. Manual for Staging of Cancer 1978. Whiting Press, Chicago, 1978, pp 101–107

    Google Scholar 

  8. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  9. Fisher B, Redmond C, Wolmark N, Wieand HS: Diseasefree survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience. Cancer 48: 1273–1280, 1981

    PubMed  Google Scholar 

  10. Meyer JS, Connor RE:In vitro labeling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei. Stain Tech 52: 185–195, 1977

    PubMed  Google Scholar 

  11. Meyer JS, Bauer WC, Rao BR: Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. Lab Invest 39: 225–235, 1978

    PubMed  Google Scholar 

  12. Meyer JS, Stevens SC, White WL, Hixon B: Estrogen receptor assay of carcinomas of the breast by a simplified dextran-charcoal method. Am J Clin Pathol 70: 655–664, 1978

    PubMed  Google Scholar 

  13. Pichon MF, Milgrom E: Characterization and assay of progesterone receptor in human mammary carcinoma. Cancer Res 37: 464–471, 1977

    PubMed  Google Scholar 

  14. Meyer JS, Prey MU, Babcock DS, McDivitt RW: Breast carcinoma cell kinetics, morphology, stage, and host characteristics. Lab Invest 54: 41–51, 1986

    PubMed  Google Scholar 

  15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  16. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York, 1980

    Google Scholar 

  17. Cox DR, Oates D: Analysis of Survival Data. Chapman and Hall, London, 1984

    Google Scholar 

  18. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS, Wheeler JE: Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG Study. Breast Cancer Res Treat 5: 3–10, 1985

    PubMed  Google Scholar 

  19. Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 40: 1890–1896, 1980

    PubMed  Google Scholar 

  20. Steel GG: Cell loss as a factor in the growth of human tumours. Eur J Cancer 3: 381–387, 1967

    PubMed  Google Scholar 

  21. Steel GG: Cytokinetics of Neoplasia. In: Holland JF, Frei E III, (eds) Cancer Medicine. Lea & Febiger, Philadelphia, 1982, pp 177–189

    Google Scholar 

  22. Meyer JS: Growth and cell kinetic measurements in human tumors. Path Annu 16(2): 53–81, 1981

    Google Scholar 

  23. Fisher B, Slack N, Katrych D, Wolmark N: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynec Obstet 140: 528–534, 1975

    PubMed  Google Scholar 

  24. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917–2924, 1980

    PubMed  Google Scholar 

  25. McGuire WL, Clark GM, Dressler LG, Owens MA: Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1: 19–23, 1986

    PubMed  Google Scholar 

  26. Sears HF, Janus C, Levy W, Hopson R, Creech R, Grotzinger P: Breast cancer without axillary metastases. Are there high-risk biologic subpopulations? Cancer 50: 1820–1827, 1982

    PubMed  Google Scholar 

  27. Stewart JF, Rubens RD, Millis RR, King RJB, Hayward JL: Steroid receptors and prognosis in operable (stage I and II) breast cancer. Eur J Cancer Clin Oncol 19: 1381–1387, 1983

    PubMed  Google Scholar 

  28. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F: The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 57: 1171–1180, 1986

    PubMed  Google Scholar 

  29. Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Ing DR, Pihl A: Estrogen receptors and longterm prognosis in breast cancer. Cancer 53: 2525–2529, 1984

    PubMed  Google Scholar 

  30. Howat JMT, Barnes DM, Harris M, Swindell R: The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Brit J Cancer 47: 629–640, 1983

    PubMed  Google Scholar 

  31. Clark GM, Osborne CK, McGuire WL: Estrogen receptor status and tumor size identify a subgroup from 1461 nodenegative breast cancer patients at high risk for recurrence and death. J Clin Oncol, 1987, in press

  32. Meyer JS: Potential value of cell kinetics in management of cancers of unknown origin. In: Fer MF, Greco FA, Oldham RK, (eds) Poorly Differentiated Neoplasms and Tumors of Unknown Origin. Grune and Stratton, Orlando, 1986, pp 519–539

    Google Scholar 

  33. Land H, Parada LF, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 222: 771–778, 1983

    PubMed  Google Scholar 

  34. Slamon DJ, diKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224: 256–262, 1984

    PubMed  Google Scholar 

  35. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    PubMed  Google Scholar 

  36. Meyer JS, McDivitt RW: Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 54: 160–164, 1986

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Washington University School of Medicine, St. Louis, Mo., St. Luke's Hospital, 232 S. Woods Mill Road, 63017, Chesterfield, MO, USA

    John Strauch Meyer

  2. Division of Biostatistics, Washington University School of Medicine, St. Louis, Mo., USA

    Michael Province

  3. The Jewish Hospital of St. Louis, USA

    John Strauch Meyer

Authors
  1. John Strauch Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Province
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer, J.S., Province, M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Tr 12, 191–204 (1988). https://doi.org/10.1007/BF01805940

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805940

Key words

Search

Navigation